A long-term growth hormone user expressed interest in experimenting with a Tesamorelin and Ipamorelin combination to improve therapeutic IGF-1 levels. They noted concerns about the potential for secretagogues to downregulate over time but sought to achieve a target serum IGF-1 range of 300-350 ng/ml.